

PROPOSED DEBT CAPITALISATION

1. INTRODUCTION

- 1.1. The Board of Directors of iX Biopharma Ltd. (the “**Company**” and together with its subsidiaries, the “**Group**”) (the “**Board**” or the “**Directors**”) wishes to announce that the Company has entered into a Debt Capitalisation Agreement with Mr. Lee Vincent Seng Yong (the “**Creditor**”) on 3 October 2026 (the “**Agreement**”) to capitalise the debt owing to the Creditor under a loan agreement dated 14 February 2025 (as amended, supplemented, assigned and novated from time to time, the “**Loan Agreement**”), through the issuance of new ordinary shares in the capital of the Company. The obligations of iX Syrx Pty Ltd, a wholly-owned subsidiary of the Company, as borrower under the Loan Agreement were novated to the Company on 3 October 2026, and the debt under the Loan Agreement is accordingly owing by the Company.

2. THE DEBT CAPITALISATION AGREEMENT

- 2.1. Pursuant to the Agreement, the Company and the Creditor have agreed that the aggregate debt of Australian Dollar (“**A\$**”) 1,700,000, equivalent to Singapore Dollar (“**S\$**”) 1,509,600 based on an exchange rate of A\$1.00:S\$0.888, being the outstanding principal amount (exclusive of all interest accrued thereon), owing by the Company to the Creditor under the Loan Agreement as at the date of the Agreement (“**Capitalised Debt**”), shall be capitalised and satisfied through the allotment and issuance of 2,682,779 new ordinary shares in the capital of the Company (“**Capitalisation Shares**”) at an issue price of S\$0.5627 (“**Issue Price**”) for each Capitalisation Share (“**Proposed Debt Capitalisation**”).
- 2.2. The Capitalisation Shares will be allotted and issued in full and final settlement of the Capitalised Debt.

3. THE PROPOSED DEBT CAPITALISATION

3.1. The Capitalisation Shares

- 3.1.1. As at the date of this announcement, the Capitalisation Shares represent approximately 0.25% of the existing issued and paid-up share capital of the Company comprising 1,093,315,474 fully paid-up ordinary shares in the capital of the Company (“**Shares**”) and will represent approximately 0.24% of the enlarged issued and paid-up share capital of the Company of 1,095,998,253 Shares.
- 3.1.2. The Proposed Debt Capitalisation will be undertaken by way of an exempt offering in Singapore in accordance with Section 272A (Small Offers) of the Securities and Futures Act 2001 of Singapore. Accordingly, no prospectus, offer document or offer information statement will be issued by the Company in connection with the Proposed Debt Capitalisation.
- 3.1.3. Pursuant to Rule 806 of the Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”), the allotment and issuance of the Capitalisation Shares to the Creditor will be made pursuant to the general share issue mandate (“**General Mandate**”) approved by the shareholders of the Company at its annual general meeting held on 24 October 2025 (“**2025 AGM**”).

- 3.1.4. The subscription of the Capitalisation Shares will not result in the transfer of a “controlling interest” which would require specific shareholders’ approval pursuant to Rule 803 of the Catalist Rules.
- 3.1.5. The Company is not undertaking any share borrowing arrangements in connection with the Proposed Debt Capitalisation.
- 3.1.6. No placement agent was appointed or is to be appointed in connection with the Proposed Debt Capitalisation and for the allotment and issuance of the Capitalisation Shares. No introducer fee, commission, fee or other selling or promotional expense is payable or incurred by the Company in connection with the Proposed Debt Capitalisation, other than those incurred for administrative or professional services.

3.2. The Issue Price

- 3.2.1. The Issue Price of S\$0.5627 per Capitalisation Share represents the volume weighted average price of S\$0.5627 per Share for trades done on the Singapore Exchange Securities Trading Limited (“SGX-ST”) on 2 October 2026, being the last full market day preceding the date of the Agreement.
- 3.2.2. The Issue Price was determined after arm’s length negotiations between the Company and the Creditor, taking into account, *inter alia*, the prevailing market conditions.

4. INFORMATION ON THE CREDITOR

- 4.1. The Creditor is a private businessman based in Australia. He is an existing shareholder of the Company holding 2,100,000 Shares, representing approximately 0.19% of the Company’s existing issued share capital. Following the allotment and issuance of the 2,682,779 Capitalisation Shares, the Creditor will hold 4,782,779 Shares, representing approximately 0.44% of the enlarged issued share capital of the Company of 1,095,998,253 Shares.
- 4.2. The Creditor has confirmed to the Company, *inter alia*, that:
 - (a) the Capitalisation Shares will only be issued to the Creditor and not to any other party;
 - (b) he is not a restricted person under Rule 812 of the Catalist Rules;
 - (c) save as disclosed in this announcement, he does not hold any legal or beneficial interest in any shares or other securities of the Company, and has no outstanding options or rights (including pre-emption rights) over any shares in the Company;
 - (d) he will be the legal and beneficial owner of the Capitalisation Shares upon their allotment and issuance and will not hold any of the Capitalisation Shares in trust or for the benefit of any other person, no other shareholder of the Company holds any Shares in trust or for his benefit, and he does not have any shareholders’ agreement or other arrangement (whether oral or in writing) with other shareholders of the Company governing his rights as a shareholder of the Company;
 - (e) he is not acting in concert with any other person, and has not entered into any agreement, arrangement or understanding (whether oral or in writing) with any person to act as parties in concert, in relation to shares in the Company;
 - (f) save for his shareholding in the Company and his interest as creditor under the Loan Agreement, the Creditor does not have any other connections (including any business relationship) with the Company, its subsidiaries, Directors or substantial shareholders;

- (g) the Capitalisation Shares will not be issued to transfer a controlling interest in the Company; and
- (h) there are no share borrowing arrangements for the Proposed Debt Capitalisation, and the Capitalisation Shares will be issued in full and final settlement of the Capitalised Debt.

5. SALIENT TERMS OF THE AGREEMENT

5.1. Subscription for Capitalisation Shares

Pursuant to the Agreement, the Company will allot and issue the Capitalisation Shares to the Creditor at the Issue Price in consideration for, and in full satisfaction of, the Capitalised Debt. The Capitalised Debt will be applied in full towards the aggregate Issue Price for the Capitalisation Shares. No cash consideration will be payable by the Creditor and, accordingly, the Company will not receive any cash proceeds from the Proposed Debt Capitalisation.

5.2. Ranking

The Capitalisation Shares, when allotted and issued, shall be free from all claims, charges, liens, mortgages, securities, pledges, equities, encumbrances and other interests whatsoever and shall rank *pari passu* in all respects with and carry all rights similar to existing Shares as at the Completion Date, except that they will not rank for any dividend, right, allotment or other distributions, the record date for which falls on or before the Completion Date.

5.3. Conditions Precedent

5.3.1. Completion of the Proposed Debt Capitalisation pursuant to the Agreement is conditional upon, *inter alia*, the following conditions:

- (a) the allotment and issuance of the Capitalisation Shares at the Issue Price to the Creditor being made pursuant to the General Mandate, remaining in full force and effect as at the Completion Date, and the Creditor not being a restricted person under Rule 812 of the Catalist Rules in relation to the Proposed Debt Capitalisation;
- (b) the listing and quotation notice being obtained from SGX-ST approving, *inter alia*, the listing of and quotation for the Capitalisation Shares on the Catalist Board of the SGX-ST and such approval not having been revoked or amended and, where such approval is subject to conditions, such conditions being acceptable to the Company, and to the extent that any conditions for the listing of and quotation for the Capitalisation Shares on SGX-ST are required to be fulfilled on or before the Completion Date, they are so fulfilled;
- (c) the subscription for the Capitalisation Shares not being prohibited by any statute, order, rule, regulation or directive promulgated or issued after the date of the Agreement by any legislative, executive or regulatory body or authority of the Republic of Singapore (including without limitation, SGX-ST, the Monetary Authority of Singapore and/or the Securities Industry Council of Singapore) or elsewhere which is applicable to the Company or the Creditor; and
- (d) the representations, warranties and undertakings of the Creditor and the Company under the Agreement remaining true, accurate and not misleading in all respects as at the date of the Agreement and up to and including the Completion Date,

(each, a “**Condition**” and collectively, the “**Conditions**”).

5.3.2. If any Condition is not fulfilled and if such non-fulfilment is not waived by the Creditor and the Company on or before 31 December 2026 (or such other date as the Company and the Creditor may agree in writing), the Agreement shall cease and determine. In that event, the Company and the Creditor shall be released and discharged from their respective obligations under the Agreement, other than the Surviving Clauses (as defined in the Agreement), and the Company and the Creditor shall not have any claim against each other under the Agreement, save in respect of any antecedent breach of the Agreement.

5.4. **Completion**

5.4.1. The completion of the Proposed Debt Capitalisation ("**Completion**") shall take place no later than five (5) business days after all Conditions have been fulfilled or waived, or such other date as may be agreed between the Company and the Creditor (the "**Completion Date**").

5.4.2. Upon Completion, the Capitalised Debt will be deemed fully repaid and discharged and the Creditor will release and discharge the securities granted in connection with the Loan Agreement.

5.5. **Company's Representations, Warranties and Undertakings**

The Company undertakes to the Creditor that it will promptly notify the Creditor of any development or event which has or may have the potential of rendering or will render untrue or incorrect any of its representations and warranties under the Agreement and take such reasonable steps to remedy or rectify the same.

6. **RATIONALE OF THE PROPOSED DEBT CAPITALISATION**

6.1. **Rationale**

6.1.1. The Group has made significant progress in the United States ("**U.S.**") over the past year. The Company was awarded a US\$41 million development contract by the U.S. Government to fund the development of Wafermine®, its patented sublingual ketamine wafer for the treatment of acute moderate to severe pain. On 7 September 2026, the Company announced that the U.S. Government had opened an emergency use pathway for drugs to treat moderate-to-severe acute pain in military casualties, enabling the Company to advance its Emergency Use Authorization submission for Wafermine® to the U.S. Food and Drug Administration. In parallel, the Group is building its commercial presence in the U.S. compounding pharmacy market, including through the relocation of its manufacturing equipment to the U.S. from its facility in Australia.

6.1.2. As the Group enters this next phase of growth, and in order to preserve the Group's cash resources for the execution of these initiatives, the Directors have decided to undertake the Proposed Debt Capitalisation to strengthen the Group's capital base. The Proposed Debt Capitalisation is considered to be in the best interests of the Group and is intended to achieve the following objectives:

- (a) reduce the Group's indebtedness and strengthen its balance sheet;
- (b) improve the Group's net asset and working capital position; and
- (c) preserve cash resources by eliminating the need to repay the Capitalised Debt in cash.

6.1.3. The Proposed Debt Capitalisation also reflects the Creditor's confidence in the Group's strategy and long-term prospects, as the Creditor has elected to receive Shares in full settlement of the Capitalised Debt rather than cash repayment.

6.1.4. Upon Completion, the Group's liabilities will be reduced by the amount of the Capitalised Debt, with a corresponding increase in its net assets. Based on the latest audited financial statements of the Group for the financial year ended 30 June 2026 ("FY2026"), the Group had a net current asset position of approximately S\$8.60 million and a net asset position of approximately S\$15.40 million as at 30 June 2026.

6.2. Confirmations by the Directors

The Directors are of the opinion that, as at the date of this announcement, after taking into consideration the present bank facilities available to the Group and the working capital available to the Group, the Group has sufficient working capital to meet its present requirements.

7. FINANCIAL EFFECTS OF THE PROPOSED DEBT CAPITALISATION

7.1. The pro forma financial effects of the Proposed Debt Capitalisation set out below have been prepared based on the latest audited consolidated financial statements of the Group for FY2026. The financial effects are strictly for illustrative purposes only and do not necessarily reflect the actual future financial position and results of the Group following Completion.

7.2. For the purpose of illustrating the financial effects of the Proposed Debt Capitalisation, the financial effects have been computed based on, *inter alia*, the following assumptions:

- (a) the financial effects on the Group's net tangible assets ("NTA") attributable to the equity holders of the Company and the NTA per Share are computed assuming that the Proposed Debt Capitalisation was completed on 30 June 2026;
- (b) the financial effects on the Group's loss attributable to the equity holders of the Company and the loss per Share are computed assuming that the Proposed Debt Capitalisation was completed on 1 July 2025; and
- (c) the Capitalised Debt is translated at the exchange rate of A\$1.00:S\$0.888.

7.3. Share Capital

	Before the Proposed Debt Capitalisation	After the Proposed Debt Capitalisation
Number of Shares*	1,093,315,474	1,095,998,253
Share Capital (S\$'000)	127,177	128,686

*Based on the number of issued Shares as at the date of this announcement.

7.4. NTA per Share

	Before the Proposed Debt Capitalisation	After the Proposed Debt Capitalisation
NTA attributable to equity holders of the Company (S\$'000)	15,394	16,903
Number of Shares*	1,093,315,474	1,095,998,253
NTA per Share (Singapore cents)	1.41	1.54

*Based on the number of issued Shares as at the date of this announcement.

7.5. Loss per Share (“LPS”)

	Before the Proposed Debt Capitalisation	After the Proposed Debt Capitalisation
Loss attributable to equity holders of the Company (S\$'000)	(7,993)	(7,993)
Weighted average number of Shares	965,015,000	967,698,000
LPS (Singapore cents)	(0.83)	(0.83)

8. MANDATE FOR THE ISSUANCE OF THE CAPITALISATION SHARES

- 8.1. The Capitalisation Shares will be allotted and issued pursuant to the General Mandate, which grants authority to the Directors to, *inter alia*, allot and issue new Shares not exceeding 100% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) as at the date of the 2025 AGM after adjusting for, *inter alia*, any new Shares arising from the conversion or exercise of warrants outstanding and subsisting at the time the resolution was passed, and of which the aggregate number of Shares to be issued other than on a *pro rata* basis to existing shareholders of the Company shall not exceed 50% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) as at the date of the 2025 AGM.
- 8.2. As at the date of the 2025 AGM, the issued and paid-up share capital of the Company was 888,818,913 Shares. Following the 2025 AGM, the Company issued an additional 56,278,942 new Shares pursuant to the exercise of issued warrants and 100,000 new Shares pursuant to the outstanding share awards under the iX Performance Share Plan that were existing at the time the General Mandate was passed, following which the number of issued Shares of the Company increased to 945,197,855 Shares. Accordingly, the maximum number of Shares that may be issued other than on a *pro rata* basis under the General Mandate is 472,598,927 Shares.
- 8.3. Following the 2025 AGM, the Company allotted and issued an aggregate of 142,800,000 new Shares other than on a *pro rata* basis under the General Mandate, comprising (a) 67,000,000 new Shares on 31 October 2025 pursuant to a placement announced on 28 October 2025; and (b) 75,800,000 new Shares on 24 February 2026 pursuant to a placement announced on 12 February 2026. Accordingly, the Company may issue up to a further 329,798,927 Shares other than on a *pro rata* basis.
- 8.4. The proposed allotment and issuance of 2,682,779 Capitalisation Shares will fall within the maximum number of 329,798,927 Shares that may be issued pursuant to the General Mandate on a non-*pro rata* basis, and as such, the prior approval of shareholders of the Company is not required for the allotment and issue of the Capitalisation Shares under the Proposed Debt Capitalisation.

9. ADDITIONAL LISTING APPLICATION

The Company will be applying to the SGX-ST, through its sponsor, UOB Kay Hian Private Limited, for the dealing in, listing of and quotation for the Capitalisation Shares on the Catalist and will make the necessary announcement(s) upon receipt of the listing and quotation notice from SGX-ST.

10. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

None of the Directors or substantial shareholders of the Company or any of their respective associates has any interest, direct or indirect, in the Proposed Debt Capitalisation, other than through their respective shareholding interests in the Company (if any).

11. DOCUMENTS AVAILABLE FOR INSPECTION

A copy of the Agreement will be available for inspection during normal business hours at the registered office of the Company at 20 Collyer Quay, #11-07, Singapore 049319 for a period of three (3) months commencing from the date of this announcement.

12. FURTHER ANNOUNCEMENTS

The Company will continue to keep its shareholders updated and release announcements relating to the Proposed Debt Capitalisation (including any material developments and progress made) as may be appropriate from time to time.

13. RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm after making all reasonable enquiries, that to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Proposed Debt Capitalisation, the Company and its subsidiaries in relation to the Proposed Debt Capitalisation, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading. Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this announcement in its proper form and context.

14. CAUTIONARY STATEMENT

Shareholders and potential investors should note that the Proposed Debt Capitalisation is subject to the fulfilment of, *inter alia*, the conditions set out under the Agreement, and accordingly, should exercise caution when trading in the Shares of the Company. Persons who are in doubt as to the action they should take should consult their legal, financial, tax or other professional advisers.

By Order of the Board
IX BIOPHARMA LTD.

Gwendolin Lee Soo Fern
Company Secretary

5 October 2026

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor").

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone: (65) 6590 6881.